mRNA

News

Another mRNA company gets snapped up as Merck buys Exelead

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead.

News

Look out GSK, Pfizer and BioNTech are coming for Shingrix

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion.

News

Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company.

News

AZ, Moderna say mRNA drug is promising in heart failure

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for he

News

FDA delays review of Moderna COVD jab in adolescents

The FDA has said it needs more time to review Moderna's application for emergency use of its COVID-19 vaccine mRNA-1273 in children aged 12 to 17, as it looks at data on heart inflammation

Events